Astellas Pharma EMEA Celebrates Its 10th Anniversary

For the Last Decade Astellas Has Been Enhancing Patient Care & Quality of Life Throughout Europe, the Middle East and Africa

CHERTSEY, England--()--Astellas Pharma EMEA is celebrating its 10 year anniversary. Established in 2005, following the Company’s founding through the historic merger of Japanese pharmaceutical companies Yamanouchi and Fujisawa, Astellas has, for the last ten years, committed to turning science into value for patients through its unwavering advance of research and development.

With a company ethos of CHANGING TOMORROW™, Astellas aims to contribute towards improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Over the past decade, Astellas EMEA has been committed to developing and refining its specialist expertise in six priority therapeutic areas including urology, oncology, transplantation, anti-infectives, pain management and dermatology. These are areas in which there is an urgent need for treatments that improve patients’ lives.

Ken Jones, President and Chief Executive Officer of EMEA Operations at Astellas, “Astellas is proud of its achievements over the last ten years. In the past decade we have been able to enhance and help the lives of those patients affected by life limiting or life altering conditions. Our dedication to research, our patients, stakeholders and employees will continue to grow and develop over the next ten years and we are looking forward to an exciting future.”

Global development

Astellas has built a robust global oncology development network and has established collaborations with key organisations at the forefront of cancer research. Over the past ten years, Astellas’ focus on global development has led to the recent launch of several major new medicines, including new classes of treatment for prostate cancer, overactive bladder and the hospital-acquired infection, Clostridium difficile. Astellas continues to strive to improve patients’ lives by focusing on disease areas where there is a vital need for better treatments. Astellas EMEA has eight new treatments in late development.

Corporate social responsibility

As an organisation, Astellas is committed to corporate social responsibility and supports a range of local and global health causes, including Action on Fistula. This is a ground-breaking three year initiative aimed at transforming the lives of women in Kenya living with a stigmatising condition, caused by prolonged obstructive labour called obstetric fistula.

Across Europe, offices unite annually on CHANGING TOMORROW™ day when Astellas donates working time to enable employees to volunteer at local charities. The Astellas European Foundation, established with funding from Astellas, operates independently from the company and provides three annual grants for academic researchers in the fields of Functional Urology/Uro-Gynaecology, Uro-Oncology and Transplantation.

People

Astellas Pharma EMEA is responsible for business across Europe, the Middle East and Africa. Headquartered near London, UK, it employs over 4,500 people and is established in 40 countries across the region, overseeing a major research and development (R&D) centre in the Netherlands as well as several manufacturing plants.

- ends -

About Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd. operates in 40 countries across Europe, the Middle East and Africa, and is the EMEA regional business of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation's focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas’ presence in Europe also includes an R&D site and three manufacturing plants. The company employs over 4,500 people across the EMEA region. In 2013 Astellas was awarded SCRIP Pharmaceutical Company of the Year in recognition of its commercial success and pipeline development. For more information about Astellas Pharma Europe Ltd., please visit www.astellas.eu.

May 2015
APEL/15/0034/EU

Contacts

Astellas Contact:
Mindy Dooa
Senior Director, Communications
Mob: +44 (0) 7826 912 339
Email: mindy.dooa@astellas.com

Contacts

Astellas Contact:
Mindy Dooa
Senior Director, Communications
Mob: +44 (0) 7826 912 339
Email: mindy.dooa@astellas.com